World Heart Novacor LVAS Transplant Alternative Trial Enrollment At 28
This article was originally published in The Gray Sheet
Executive Summary
World Heart has enrolled 28 out of 40 patients to be evaluated in the feasibility phase of its INTrEPID trial for its Novacor left ventricular assist system as an alternative-to-transplant destination therapy